title: [Treatment of nonalcoholic steatohepatitis].
abstract: NASH associates steatosis with parenchymal inflammation and signs of hepatocellular injuy and even apoptosis. This leads in a minority of patients to fibrosis and in the long term to cirrhosis. NASH regularly occurs in a metabolic context characterized by insulin resistance. Several drugs have been tested in randomized controlled studies. Glitazones improve insulin resistance and also NASH, but are associated with side effects particularly unwelcome in NASH patients. Ursodesoxycholic acid, an hydrophilic biliary acid with hepatoprotective properties, does not improve the histological lesions of NASH. Vitamin E is the only compound which showed so far a positive effect without relevant side effects. However, it is too early to recommend its long-term use in this indication. Finally, the best treatment is not with drugs, but relies on behavioural changes: NASH patients should regularly exercise!
authors: Département de chirurgie et de médecine viscérale, Inselspital, université de Berne.
authors: Anne-Catherine
authors: AC
authors: Bürgi
authors: Jean-François
authors: JF
authors: Dufour
mesh_terms: D017209:Apoptosis / Q000502:physiology; D050110:Bariatric Surgery / Q000706:statistics & numerical data; D005234:Fatty Liver / Q000150:complications / Q000628:therapy*; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology; D065626:Non-alcoholic Fatty Liver Disease; D004364:Pharmaceutical Preparations; D013312:Stress, Physiological / Q000502:physiology
chemical_list: D004364:Pharmaceutical Preparations